Labcorp Reports Strong 2025 Financials, $450M Share Repurchase, & Progress on Key Legal Cases
LH sits 37% above its 52-week low of $209.375 on light trading volume (0.3× avg).
Summary
Labcorp reported strong 2025 financial results with significant revenue and EPS growth, alongside a substantial $450 million share repurchase. The company also provided updates on key legal proceedings, including appealing a major patent infringement judgment and reaching settlements in principle for two class action lawsuits.
Key Events · Earnings and Guidance · LH
-
Strong 2025 Financial Performance
Reported a 7.2% increase in revenues to $13.95 billion and an 18.3% rise in diluted EPS to $10.46 for the fiscal year ended December 31, 2025, building on previously announced strong results.
-
Significant Share Repurchase Program
Repurchased $450.0 million of common stock in 2025, with $830.4 million remaining under the current authorization, demonstrating a strong commitment to returning capital to shareholders.
-
Updates on Major Legal Proceedings
The company is appealing a $374.6 million patent infringement judgment (plus ongoing royalties) in the Ravgen case and is defending a Texas Medicaid lawsuit. Separately, settlements in principle were reached for the AMCA data breach and Meta Pixel class action lawsuits, moving these towards resolution.
-
Increased Restructuring Charges
Recorded $127.2 million in restructuring and other charges in 2025, up from $46.0 million in 2024, primarily due to asset impairments related to the restructuring of its Early Development business.
Analysis · LH · Industrial Applications And Services
Labcorp's annual report for 2025 details robust financial performance, including a 7.2% increase in revenues to $13.95 billion and an 18.3% rise in diluted EPS to $10.46. The company also executed a substantial $450.0 million share repurchase program in 2025, with $830.4 million remaining authorized, signaling confidence and commitment to shareholder returns. This positive financial news is balanced by updates on significant legal matters: the company continues to vigorously appeal a $374.6 million patent infringement judgment (plus ongoing royalties) in the Ravgen case and is defending a Texas Medicaid lawsuit. However, positive steps were made with settlements in principle for the AMCA data breach and Meta Pixel class action lawsuits, moving towards resolution of these long-standing litigations. Additionally, the company recorded increased restructuring charges of $127.2 million, primarily related to asset impairments in its Early Development business.
At the time of this filing, LH was trading at $287.75 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $23.9B. The 52-week trading range was $209.38 to $293.72. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.